most effective glp-1 for obesity treatment 2025 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs 📚𝗧𝗵𝗲𝗿𝗲'𝘀 𝗮 𝗻𝗲𝘄 𝘀𝘁𝘂𝗱𝘆 𝗶𝗻

doi: 10.1111/mpp.12661 12 DecrosA.MahillonM.GenardM.LienardC.Lima-MendezG.GilmerD.et al

Additionally, government initiatives aimed at tackling non-communicable diseases and growing awareness about weight management have accelerated market growth

Imfinzi (durvalumab) Disease area(s): Oncology Manufacturer(s): AstraZeneca 2024 Sales (USD): $4.72 billion Why it sold so well: In 2024, AstraZenecas Imfinzi experienced strong sales growth, driven by expanded indications and robust clinical trial results

How Retailers and CPG Brands Can Unlock Growth in the Era of GLP-1 Medications The rapid adoption of GLP-1 medications is fundamentally shifting dietary priorities across CPG categories, with social media amplifying interest among weight-conscious consumers